Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) CFO Sells $621,259.21 in Stock

Key Points

• Kiniksa Pharmaceuticals CFO Mark Ragosa sold 18,889 shares of stock for a total of $621,259.21, reducing his ownership by 41.15% to 27,009 shares worth approximately $888,326.01.
• Despite recent insider selling, Kiniksa traded at $32.72 with a market cap of $2.39 billion and positive quarterly earnings that beat analyst estimates by $0.05.
• Kiniksa Pharmaceuticals received multiple analyst upgrades, including a strong-buy rating from Wall Street Zen, and has a consensus rating of "Buy" with an average price target of $41.17.

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - Get Free Report) CFO Mark Ragosa sold 18,889 shares of the firm's stock in a transaction that occurred on Monday, August 4th. The stock was sold at an average price of $32.89, for a total transaction of $621,259.21. Following the transaction, the chief financial officer directly owned 27,009 shares in the company, valued at $888,326.01. This represents a 41.15% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Mark Ragosa also recently made the following trade(s):

• On Tuesday, June 3rd, Mark Ragosa sold 18,299 shares of Kiniksa Pharmaceuticals International stock. The shares were sold at an average price of $28.80, for a total transaction of $527,011.20.

Kiniksa Pharmaceuticals International Stock Performance

Shares of NASDAQ:KNSA traded down $0.96 during mid-day trading on Friday, reaching $32.15. 675,329 shares of the company's stock were exchanged, compared to its average volume of 703,396. The firm has a market capitalization of $2.35 billion, a price-to-earnings ratio of 803.95 and a beta of 0.14. The business's fifty day moving average price is $28.95 and its 200-day moving average price is $24.59. Kiniksa Pharmaceuticals International, plc has a twelve month low of $17.82 and a twelve month high of $33.98.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) last issued its quarterly earnings results on Tuesday, July 29th. The company reported $0.23 EPS for the quarter, topping analysts' consensus estimates of $0.18 by $0.05. Kiniksa Pharmaceuticals International had a net margin of 0.90% and a return on equity of 1.05%. The company had revenue of $156.80 million for the quarter, compared to analyst estimates of $145.21 million. Analysts predict that Kiniksa Pharmaceuticals International, plc will post -0.55 EPS for the current fiscal year.

Hedge Funds Weigh In On Kiniksa Pharmaceuticals International

A number of hedge funds have recently bought and sold shares of the company. Corebridge Financial Inc. raised its stake in Kiniksa Pharmaceuticals International by 3.6% during the first quarter. Corebridge Financial Inc. now owns 15,979 shares of the company's stock worth $355,000 after buying an additional 549 shares during the last quarter. GAMMA Investing LLC increased its position in shares of Kiniksa Pharmaceuticals International by 84.8% during the first quarter. GAMMA Investing LLC now owns 1,238 shares of the company's stock worth $27,000 after acquiring an additional 568 shares in the last quarter. Sound View Wealth Advisors Group LLC increased its position in shares of Kiniksa Pharmaceuticals International by 4.0% during the first quarter. Sound View Wealth Advisors Group LLC now owns 14,657 shares of the company's stock worth $326,000 after acquiring an additional 568 shares in the last quarter. Martingale Asset Management L P increased its position in shares of Kiniksa Pharmaceuticals International by 1.3% during the first quarter. Martingale Asset Management L P now owns 50,000 shares of the company's stock worth $1,111,000 after acquiring an additional 640 shares in the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in Kiniksa Pharmaceuticals International by 4.6% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 22,843 shares of the company's stock worth $507,000 after purchasing an additional 1,002 shares during the last quarter. Institutional investors own 53.95% of the company's stock.

Analysts Set New Price Targets

A number of brokerages recently issued reports on KNSA. Jefferies Financial Group lifted their price objective on shares of Kiniksa Pharmaceuticals International from $45.00 to $54.00 and gave the company a "buy" rating in a research note on Tuesday, July 29th. Wells Fargo & Company lifted their price objective on shares of Kiniksa Pharmaceuticals International from $30.00 to $42.00 and gave the company an "overweight" rating in a research note on Wednesday, July 9th. Wall Street Zen upgraded shares of Kiniksa Pharmaceuticals International from a "buy" rating to a "strong-buy" rating in a research report on Saturday, August 2nd. Finally, Wedbush restated an "outperform" rating and issued a $36.00 target price on shares of Kiniksa Pharmaceuticals International in a research report on Monday, July 21st. Six research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, Kiniksa Pharmaceuticals International has an average rating of "Buy" and a consensus price target of $41.17.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.